Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

K. S. Thomas; C. A. Apfelbacher; J. R. Chalmers; E. Simpson; P. I. Spuls; L. A.A. Gerbens; H. C. Williams; J. Schmitt; M. Gabes; L. Howells; B. L. Stuart; E. Grinich; T. Pawlitschek; T. Burton; L. Howie; A. Gadkari; L. Eckert; T. Ebata; M. Boers; H. Saeki; T. Nakahara; N. Katoh

doi:10.1111/bjd.19751

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

K. S. Thomas, C. A. Apfelbacher, J. R. Chalmers, E. Simpson, P. I. Spuls, L. A.A. Gerbens, H. C. Williams, J. Schmitt, M. Gabes, L. Howells, B. L. Stuart, E. Grinich, T. Pawlitschek, T. Burton, L. Howie, A. Gadkari, L. Eckert, T. Ebata, M. Boers, H. SaekiT. Nakahara, N. Katoh

Dermatology

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. Objectives: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. Methods: A face-to-face consensus meeting was held in Tokyo, Japan (8–10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. Results: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children’s Dermatology Life Quality Index (CDLQI) for children and the Infant’s Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. Conclusions: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.

Original language	English (US)
Pages (from-to)	139-146
Number of pages	8
Journal	British Journal of Dermatology
Volume	185
Issue number	1
DOIs	https://doi.org/10.1111/bjd.19751
State	Published - Jul 2021

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/bjd.19751

Cite this

Thomas, K. S., Apfelbacher, C. A., Chalmers, J. R., Simpson, E., Spuls, P. I., Gerbens, L. A. A., Williams, H. C., Schmitt, J., Gabes, M., Howells, L., Stuart, B. L., Grinich, E., Pawlitschek, T., Burton, T., Howie, L., Gadkari, A., Eckert, L., Ebata, T., Boers, M., ... Katoh, N. (2021). Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 185(1), 139-146. https://doi.org/10.1111/bjd.19751

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. / Thomas, K. S.; Apfelbacher, C. A.; Chalmers, J. R. et al.
In: British Journal of Dermatology, Vol. 185, No. 1, 07.2021, p. 139-146.

Research output: Contribution to journal › Article › peer-review

Thomas, KS, Apfelbacher, CA, Chalmers, JR, Simpson, E, Spuls, PI, Gerbens, LAA, Williams, HC, Schmitt, J, Gabes, M, Howells, L, Stuart, BL, Grinich, E, Pawlitschek, T, Burton, T, Howie, L, Gadkari, A, Eckert, L, Ebata, T, Boers, M, Saeki, H, Nakahara, T & Katoh, N 2021, 'Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*', British Journal of Dermatology, vol. 185, no. 1, pp. 139-146. https://doi.org/10.1111/bjd.19751

@article{4f6183d1d8c84423af72abda3c6b81be,

title = "Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*",

abstract = "Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. Objectives: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. Methods: A face-to-face consensus meeting was held in Tokyo, Japan (8–10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. Results: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children{\textquoteright}s Dermatology Life Quality Index (CDLQI) for children and the Infant{\textquoteright}s Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. Conclusions: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.",

author = "Thomas, {K. S.} and Apfelbacher, {C. A.} and Chalmers, {J. R.} and E. Simpson and Spuls, {P. I.} and Gerbens, {L. A.A.} and Williams, {H. C.} and J. Schmitt and M. Gabes and L. Howells and Stuart, {B. L.} and E. Grinich and T. Pawlitschek and T. Burton and L. Howie and A. Gadkari and L. Eckert and T. Ebata and M. Boers and H. Saeki and T. Nakahara and N. Katoh",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2021",

month = jul,

doi = "10.1111/bjd.19751",

language = "English (US)",

volume = "185",

pages = "139--146",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials

T2 - results of the HOME VII consensus meeting*

AU - Thomas, K. S.

AU - Apfelbacher, C. A.

AU - Chalmers, J. R.

AU - Simpson, E.

AU - Spuls, P. I.

AU - Gerbens, L. A.A.

AU - Williams, H. C.

AU - Schmitt, J.

AU - Gabes, M.

AU - Howells, L.

AU - Stuart, B. L.

AU - Grinich, E.

AU - Pawlitschek, T.

AU - Burton, T.

AU - Howie, L.

AU - Gadkari, A.

AU - Eckert, L.

AU - Ebata, T.

AU - Boers, M.

AU - Saeki, H.

AU - Nakahara, T.

AU - Katoh, N.

PY - 2021/7

Y1 - 2021/7

N2 - Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. Objectives: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. Methods: A face-to-face consensus meeting was held in Tokyo, Japan (8–10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. Results: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children’s Dermatology Life Quality Index (CDLQI) for children and the Infant’s Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. Conclusions: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.

AB - Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. Objectives: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. Methods: A face-to-face consensus meeting was held in Tokyo, Japan (8–10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. Results: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children’s Dermatology Life Quality Index (CDLQI) for children and the Infant’s Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. Conclusions: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.

UR - http://www.scopus.com/inward/record.url?scp=85100575246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100575246&partnerID=8YFLogxK

U2 - 10.1111/bjd.19751

DO - 10.1111/bjd.19751

M3 - Article

C2 - 33393074

AN - SCOPUS:85100575246

SN - 0007-0963

VL - 185

SP - 139

EP - 146

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 1

ER -

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this